Table 1 Baseline clinical characteristics of patients with NSCLC
From: IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer
|  | All patients n = 39 | IL- 17A low expression n = 19 | IL- 17A high expression n = 20 | P value |
|---|---|---|---|---|
Age (years) median (range) | 61.2 (36–87) | 60.8 (36–78) | 61.5 (46–87) | 0.840 |
Gender | ||||
 Male | 27 (69.3) | 13 (68.4) | 14 (70) | 0.915 |
 Female | 12 (30.7) | 6 (36.6) | 6 (30) | |
Histology | ||||
 Adenocarcinoma | 28 (71.8) | 14 (73.6) | 14 (70) | 0.999 |
 Squamous | 11 (28.2) | 5 (26.4) | 6 (30) | |
Smoking status | ||||
 Current/former | 21 (53.9) | 8 (42.1) | 13 (65) | 0.205 |
 Never | 18 (46. 1) | 11 (57.9) | 7 (35) | |
Tumor size (cm) | ||||
 T1 (≤ 3) | 9 (23.1) | 5 (26.3) | 4 (20) | 0.885 |
 T2 (> 3, ≤ 5) | 18 (46.2) | 8 (42.1) | 10 (50) | |
 T3 (> 5, ≤ 7) | 5 (12.8) | 2 (10.5) | 3 (15) | |
 T4 (> 7) | 7 (17.9) | 4 (21.1) | 3 (15) | |
Stage | ||||
 I | 13 (33.3) | 7 (36.8) | 6 (30) | 0.959 |
 II | 8 (20.5) | 4 (21.1) | 4 (20) | |
 III | 16 (41. 1) | 7 (36.8) | 9 (45) | |
 IV | 2 (5.1) | 1 (5.3) | 1 (5) | |
TPS (%) | ||||
 ≥ 50 | 11 (28.2) | 1 (5.2) | 10 (50) | 0.0073** |
 1–49 | 18 (46.2) | 11 (58.0) | 7 (35) | |
 < 1 | 10 (25.6) | 7 (36.8) | 3 (15) | |